Monday, August 4, 2025
Science
No Result
View All Result
  • Login
  • HOME
  • SCIENCE NEWS
  • CONTACT US
  • HOME
  • SCIENCE NEWS
  • CONTACT US
No Result
View All Result
Scienmag
No Result
View All Result
Home Science News Cancer

Blood-based Cancer Screening

January 12, 2025
in Cancer
Reading Time: 4 mins read
0
69
SHARES
623
VIEWS
Share on FacebookShare on Twitter
ADVERTISEMENT

The advent of blood-based cancer screening has brought hope and excitement to the medical community, particularly in the field of colorectal cancer (CRC). Groundbreaking advancements in laboratory science and data analytics have catalyzed the development of circulating cell-free DNA (cfDNA) assays that promise a less invasive, potentially more accessible approach to cancer detection. However, as these innovative tests begin to gain traction, particularly in the United States, it is imperative to assess their efficacy, cost-effectiveness, and impact on overall screening outcomes.

Colorectal cancer remains a significant global health challenge, accounting for a substantial burden of cancer-related morbidity and mortality. Traditional screening methods, such as fecal immunochemical testing (FIT) and sigmoidoscopy, have demonstrated remarkable success in reducing CRC incidence and mortality through the early detection of precancerous lesions and curable-stage cancers. These methods—validated through rigorous randomized controlled trials—represent the gold standard of CRC screening. The ability to detect and remove advanced precancerous lesions before they progress to cancer is a hallmark of FIT-based screening programs, which are widely implemented worldwide.

In this context, novel cfDNA-based blood tests for CRC detection are emerging as an alternative screening modality. Initial regulatory approvals for these tests in the United States have set the stage for their potential expansion to other countries. However, these tests must be evaluated against established benchmarks of screening effectiveness. One widely used FIT, the OC-Sensor, achieves sensitivities of 74% for CRC and 23% for advanced precancerous lesions, with a specificity of 94% at a 20 μg hemoglobin/g feces threshold. Comparatively, the first-generation cfDNA blood test shows an 83% sensitivity for CRC detection, 55% sensitivity for stage 1 CRC, and a modest 13% sensitivity for advanced precancerous lesions, with a specificity of 90%. While these figures are promising, they highlight a critical gap: the markedly lower sensitivity of cfDNA tests for detecting precancerous lesions, which undermines their preventive potential.

ADVERTISEMENT

The programmatic nature of CRC screening adds another layer of complexity to the comparison between FIT and cfDNA tests. FIT is typically performed annually or biennially, while current guidelines in the United States recommend triennial testing with cfDNA assays. This disparity in screening intervals raises questions about the cumulative effectiveness of cfDNA testing. For example, decision analytic models predict that annual FIT or decennial colonoscopy could reduce CRC incidence and mortality by over 70%. In contrast, triennial cfDNA testing is estimated to achieve reductions of 42% in incidence and 56% in mortality. These differences emphasize the importance of both test sensitivity and screening frequency in determining long-term outcomes.

The accessibility and acceptability of screening methods significantly influence participation rates, a crucial determinant of programmatic effectiveness. Blood tests may appeal to individuals who are reluctant to complete stool-based tests or undergo colonoscopy. By integrating CRC screening into routine blood work, cfDNA tests could potentially increase screening uptake among underserved populations. However, this potential benefit is tempered by the risk that individuals currently adhering to effective FIT-based or colonoscopy-based programs might switch to less effective cfDNA testing, inadvertently increasing CRC mortality. Model simulations suggest that for cfDNA testing to match the effectiveness of FIT, it would require a 35% higher uptake among currently unscreened individuals.

Cost considerations further complicate the adoption of cfDNA-based CRC screening. In the United States, the list price of the first-generation cfDNA test is $1,450, compared to $20 for FIT. This significant cost differential limits the feasibility of widespread cfDNA testing, particularly in low- and middle-income countries. Moreover, reducing the screening interval to increase cfDNA’s efficacy is not cost-effective at current pricing levels. Addressing the affordability of cfDNA tests will be essential for their integration into global CRC screening programs.

A pivotal challenge for cfDNA tests lies in their ability to detect advanced precancerous lesions, which are critical targets for CRC prevention. Decision models underscore that enhancing the sensitivity of blood tests for these lesions would yield greater reductions in CRC incidence and mortality than improving CRC detection alone. As such, future iterations of cfDNA assays must prioritize advancements in this area to fulfill their preventive promise.

Another concern with cfDNA-based screening is its limited organ specificity. Unlike stool-based tests, which focus solely on the colorectum, blood tests may yield ambiguous results, prompting extensive diagnostic evaluations. This lack of specificity could lead to unnecessary procedures and patient anxiety, detracting from the overall benefits of screening. The potential for false positives and diagnostic odysseys underscores the need for robust education and shared decision-making between patients and clinicians.

The introduction of cfDNA-based CRC screening tests represents a significant milestone in cancer diagnostics. However, their current performance characteristics suggest they are best suited for individuals who would otherwise remain unscreened. For the broader population, FIT and colonoscopy remain the more effective options for reducing CRC incidence and mortality. Enthusiasm for novel technologies must be tempered by rigorous evaluation of their efficacy, safety, and cost-effectiveness. Substantial improvements in cfDNA test sensitivity for early-stage CRC and precancerous lesions, coupled with competitive pricing, could herald a new era in CRC screening. Until then, the integration of cfDNA tests into existing programs must be approached with caution, ensuring that innovations enhance—rather than compromise—the effectiveness of CRC prevention efforts.

Subject of Research: Cancer screening technologies, with a focus on blood-based tests for colorectal cancer.

Article Title: Can molecular cancer signals circulating in blood help us prevent cancer-related deaths?

News Publication Date: 2025-01-12

Article Doi References: https://doi.org/10.1016/S0140-6736(24)02708-9

Keywords: colorectal cancer, cancer screening, blood-based tests, circulating cell-free DNA, faecal immunochemical testing, cost-effectiveness, advanced precancerous lesions, cancer prevention.

Share28Tweet17
Previous Post

Lung Metastasis Aspartate

Next Post

Porcine Heart Transplant

Related Posts

blank
Cancer

Rethinking Cancer Unknown Primary: From Diagnosis to Treatment

August 4, 2025
blank
Cancer

University of Bath Innovates Breakthrough Technology to Replace Injections with Pills

August 4, 2025
blank
Cancer

Breast Cancer Survival Trends in Ethiopia Revealed

August 4, 2025
blank
Cancer

Small RNA Fragments Hold Major Promise in Advancing Cancer Treatment

August 4, 2025
blank
Cancer

Survival Comparison: HER2+ Pregnancy vs. Non-Pregnancy Breast Cancer

August 4, 2025
blank
Cancer

Advancing Tumor Immunotherapy: The Role of Spatial and Single-Cell Omics in Biomarker Discovery

August 4, 2025
Next Post
blank

Porcine Heart Transplant

  • Mothers who receive childcare support from maternal grandparents show more parental warmth, finds NTU Singapore study

    Mothers who receive childcare support from maternal grandparents show more parental warmth, finds NTU Singapore study

    27529 shares
    Share 11008 Tweet 6880
  • University of Seville Breaks 120-Year-Old Mystery, Revises a Key Einstein Concept

    939 shares
    Share 376 Tweet 235
  • Bee body mass, pathogens and local climate influence heat tolerance

    640 shares
    Share 256 Tweet 160
  • Researchers record first-ever images and data of a shark experiencing a boat strike

    506 shares
    Share 202 Tweet 127
  • Warm seawater speeding up melting of ‘Doomsday Glacier,’ scientists warn

    310 shares
    Share 124 Tweet 78
Science

Embark on a thrilling journey of discovery with Scienmag.com—your ultimate source for cutting-edge breakthroughs. Immerse yourself in a world where curiosity knows no limits and tomorrow’s possibilities become today’s reality!

RECENT NEWS

  • Rethinking Cancer Unknown Primary: From Diagnosis to Treatment
  • Kushneria Pigments Trigger Cancer Cell Death via BAX/BCL-2
  • Alpha-Synuclein Levels Unnecessary for Parkinson’s Pathology
  • Green Populism: Europe’s Environmental Politics Shift

Categories

  • Agriculture
  • Anthropology
  • Archaeology
  • Athmospheric
  • Biology
  • Bussines
  • Cancer
  • Chemistry
  • Climate
  • Earth Science
  • Marine
  • Mathematics
  • Medicine
  • Pediatry
  • Policy
  • Psychology & Psychiatry
  • Science Education
  • Social Science
  • Space
  • Technology and Engineering

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 5,184 other subscribers

© 2025 Scienmag - Science Magazine

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • HOME
  • SCIENCE NEWS
  • CONTACT US

© 2025 Scienmag - Science Magazine

Discover more from Science

Subscribe now to keep reading and get access to the full archive.

Continue reading